Videos

Evidence from a matched pair comparison with a concurrent control cohort suggests that panobinostat plus gemcitabine, busulfan, and melphalan improves progression-free survival in those with relapsed or refractory multiple myeloma, especially after first transplant.

Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.

The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.

A brief review of talquetamab, a novel agent in the setting of relapsed/refractory multiple myeloma that targets GPRC5D.

Following their discussion on teclistamab, experts from the Moffit Cancer Center highlight other BCMA-targeted therapies available in the relapsed/refractory setting of multiple myeloma.

Anne-Marie Jacob shares advice for patients with multiple myeloma receiving teclistamab who are recommended for hospital admission for CRS risk.

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Expert perspectives on the advent of CAR T-cell therapy in relapsed/refractory multiple myeloma, and how its role may integrate with bispecific antibody therapy.

Before closing out their discussion on bispecific antibodies in relapsed/refractory multiple myeloma, key opinion leaders consider optimal sequencing of these agents.

Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

A review of novel treatment modalities for relapsed/refractory multiple myeloma, with a focus on selecting and sequencing bispecific antibodies and CAR T-cell therapies.

Expert panelists center discussion on a final patient case to review the identification and management of relapsed/refractory multiple myeloma.

Talha Badar, MBBS, MD, discussed ongoing trials in the treatment of chronic myeloid leukemia in chronic phase, as well as his hope for future therapies in the space.

Dr Stacey A. Cohen discusses how she typically monitors patients with stage II and III colorectal cancer during and after adjuvant therapy.

Stacey A. Cohen, MD, and Daniel H. Ahn, DO, describe the challenges of deciding which patients with colorectal cancer should receive adjuvant therapy, and the risk of over- and under-treatment in later stages.

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial.

Panelists review data from the MajesTEC-1 clinical trial and elucidate the role of teclistamab therapy in patients with relapsed/refractory multiple myeloma.

Shared insight on the value of using effective regimens upfront and optimal sequencing throughout several lines of therapy in multiple myeloma.

An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.